ELIGLUSTAT TARTRATE: Glucosylceramide Synthase Inhibitor Treatment of Type 1 Gaucher Disease.
about
Less Is More: Substrate Reduction Therapy for Lysosomal Storage DisordersEliglustat tartrate for the treatment of adults with type 1 Gaucher diseaseThe design and clinical development of inhibitors of glycosphingolipid synthesis: will invention be the mother of necessity?Stability is maintained in adults with Gaucher disease type 1 switched from velaglucerase alfa to eliglustat or imiglucerase: A sub-analysis of the eliglustat ENCORE trialTreatment of profound thrombocytopenia in a patient with Gaucher disease type 1: Is there a role for substrate reduction therapy.Case report of unexpected gastrointestinal involvement in type 1 Gaucher disease: comparison of eliglustat tartrate treatment and enzyme replacement therapyThe development and use of small molecule inhibitors of glycosphingolipid metabolism for lysosomal storage diseases.Induced pluripotent stem cell models of lysosomal storage disorders.Development of targeted therapies for Parkinson's disease and related synucleinopathiesUbiquitous transgene expression of the glucosylceramide-synthesizing enzyme accelerates glucosylceramide accumulation and storage cells in a Gaucher disease mouse model.Property-based design of a glucosylceramide synthase inhibitor that reduces glucosylceramide in the brain.In memoriam: Norman S. Radin (1920-2013).Targeting glucosylceramide synthase upregulation reverts sorafenib resistance in experimental hepatocellular carcinoma.Clinical response to eliglustat in treatment-naïve patients with Gaucher disease type 1: Post-hoc comparison to imiglucerase-treated patients enrolled in the International Collaborative Gaucher Group Gaucher Registry.Genetic Substrate Reduction Therapy: A Promising Approach for Lysosomal Storage Disorders.Outcomes after 18 months of eliglustat therapy in treatment-naïve adults with Gaucher disease type 1: The phase 3 ENGAGE trialSphingolipids, new kids on the block, promoting glomerular fibrosis in the diabetic kidney.Translational Aspects of Sphingolipid Metabolism in Renal Disorders.Pharmacotherapy of Gaucher Disease: Current and Future Options.
P2860
Q26744230-55F65D05-2C09-4180-A557-A76E6FD96EA5Q26783393-A3983306-3C6A-4CF4-9E88-DFCD28E03F99Q33409263-7D3F46AE-1542-4EF4-9F31-1A4B81641E00Q33435875-08132061-819C-4BC1-A295-EB97F350FDFCQ33443605-AC8EC71F-B9B6-4268-AEAD-FD44C3DB872FQ33692023-81100E08-1170-42A1-A941-ACFB832C1B4CQ33825097-BF169F5A-1075-47FB-B2AA-CEB9C55D3072Q33830512-72B0B533-83D6-4E0D-9DF2-FB9D4C076CD1Q34238616-B1E1885C-EA94-474E-9B5D-7B9D87379772Q35536435-924CABBD-C668-48A0-8276-14CD575350EBQ35715564-4044E19F-3236-4550-ACD2-22EA253CE0CFQ36920534-38B5D627-5422-4C23-A3E2-855E61BCCF23Q40060996-C326E598-06F5-4E7E-B28C-747FE86B72D8Q41766698-FDDF714A-1964-4C82-8C37-67E4C3292546Q42069602-F1BE17E3-6C13-4E1C-97E2-9B3F2B18FD8BQ42733053-2DECEC77-96DC-454D-9E34-4C4D5D35EE6FQ43188471-F2611BBB-0A1A-4141-A12B-A67B2A9BB6BDQ49399657-CC916D2D-621A-4E12-872A-10A087808C14Q55062298-4DC43A68-B1EA-4FD9-BAED-3F87C89D0B28
P2860
ELIGLUSTAT TARTRATE: Glucosylceramide Synthase Inhibitor Treatment of Type 1 Gaucher Disease.
description
2010 nî lūn-bûn
@nan
2010 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
ELIGLUSTAT TARTRATE: Glucosylc ...... ent of Type 1 Gaucher Disease.
@ast
ELIGLUSTAT TARTRATE: Glucosylc ...... ent of Type 1 Gaucher Disease.
@en
ELIGLUSTAT TARTRATE: Glucosylc ...... ent of Type 1 Gaucher Disease.
@nl
type
label
ELIGLUSTAT TARTRATE: Glucosylc ...... ent of Type 1 Gaucher Disease.
@ast
ELIGLUSTAT TARTRATE: Glucosylc ...... ent of Type 1 Gaucher Disease.
@en
ELIGLUSTAT TARTRATE: Glucosylc ...... ent of Type 1 Gaucher Disease.
@nl
prefLabel
ELIGLUSTAT TARTRATE: Glucosylc ...... ent of Type 1 Gaucher Disease.
@ast
ELIGLUSTAT TARTRATE: Glucosylc ...... ent of Type 1 Gaucher Disease.
@en
ELIGLUSTAT TARTRATE: Glucosylc ...... ent of Type 1 Gaucher Disease.
@nl
P2860
P921
P1433
P1476
ELIGLUSTAT TARTRATE: Glucosylc ...... ent of Type 1 Gaucher Disease.
@en
P2093
J A Shayman
P2860
P304
P577
2010-08-01T00:00:00Z